Approval · Notice of Compliance 36685 · 2026
MINT-HYDRALAZINE: Notice of Compliance 36685
Issued January 6, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36685
- Date
- January 6, 2026
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph (to align with CRP approved PM). Update to package labels
- Canadian reference product
- HYDRAZALINE (AA Pharma Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-HYDRALAZINE | Not yet assigned | — |
Medicinal ingredients
- HYDRALAZINE HCL 10 MG per TAB
- HYDRALAZINE HCL 25 MG per TAB
- HYDRALAZINE HCL 50 MG per TAB